ABGENIX, INC.

Mar 29, 06
	NEW STORY
17:10 ET	Abgenix Announces Stockholder Approval of Acquisition by Amgen
Feb 21, 06
16:00 ET	Abgenix Announces 2005 Fourth Quarter and Full Year Financial Results
Feb 14, 06
08:31 ET	Abgenix to Host Fourth Quarter and Full Year 2005 Conference Call
Jan 05, 06
08:30 ET	Abgenix to Present at JPMorgan 24th Annual Healthcare Conference
Dec 14, 05
16:06 ET	Amgen to Acquire Abgenix for $22.50 Per Share
Nov 09, 05
16:01 ET	Abgenix Appoints Jeffrey H. Knapp as Senior Vice President of Sales and Marketing
Nov 03, 05
08:05 ET	Media Notification/Webcast Notification - Amgen and Abgenix to Conduct Conference Call and Webcast Regarding Panitumumab Pivotal Study Results - November 3, 2005, 8:00 am PT
08:05 ET	Panitumumab Significantly Improves Progression-Free Survival in Phase 3 Randomized Metastatic Colorectal Cancer Study
Oct 25, 05
16:00 ET	Abgenix Announces Third Quarter 2005 Financial Results
Oct 18, 05
16:30 ET	Abgenix to Host Third Quarter 2005 Conference Call
Sep 01, 05
16:30 ET	Abgenix to Webcast Three Upcoming Conference Presentations
Aug 01, 05
09:04 ET	Abgenix and Amgen Announce FDA Grants Panitumumab Fast Track Designation for Metastatic Colorectal Cancer
Jul 26, 05
16:03 ET	Abgenix Announces Second Quarter 2005 Financial Results
Jul 19, 05
16:30 ET	Abgenix to Host Conference Call on Second Quarter 2005 Financial Results
Jun 28, 05
13:30 ET	Abgenix to Consolidate Research Facilities in Preparation for Expanded Development and Commercial Operations
Jun 08, 05
16:30 ET	Abgenix to Present at Goldman Sachs Twenty-Sixth Annual Global Healthcare Conference
May 20, 05
16:30 ET	Abgenix to Present at Needham & Company's Fourth Annual Biotechnology Conference
May 17, 05
08:01 ET	Further Phase 2 Data Confirm Panitumumab Single-Agent Antitumor Activity in Patients With Metastatic Colorectal Cancer
May 11, 05
19:30 ET	Abgenix Appoints Marc Better, Ph.D., as Vice President of Process Sciences
Apr 26, 05
18:30 ET	Phase 3 Clinical Trial Initiated to Evaluate the Use of Panitumumab Therapy For First-Line Treatment of Metastatic Colorectal Cancer
16:02 ET	Abgenix Announces First Quarter 2005 Financial Results
Apr 18, 05
06:30 ET	Abgenix to Host Conference Call on First Quarter 2005 Financial Results
Apr 15, 05
06:32 ET	Abgenix Announces Data Presentations for Panitumumab at AACR and ASCO Annual Meetings
Mar 23, 05
16:00 ET	Abgenix to Present at the Smith Barney Citigroup 2005 Healthcare Conference
Mar 18, 05
06:00 ET	Panitumumab Pivotal Trial Completes Patient Enrollment
Mar 17, 05
16:53 ET	Abgenix Files Resale Registration Statement
Mar 14, 05
09:01 ET	Abgenix and Genentech Extend Antibody Technology Licensing Agreement
Mar 04, 05
16:00 ET	Abgenix Appoints Donald R. Joseph as Senior Vice President, General Counsel and Secretary
Feb 23, 05
16:30 ET	Abgenix to Webcast Participation in SunTrust Robinson Humphrey 'Off the Cuff' Therapeutics Conference
Feb 22, 05
16:07 ET	Abgenix Announces 2004 Fourth Quarter and Full Year Financial Results
Feb 18, 05
16:30 ET	Abgenix to Present at BIO CEO & Investor Conference 2005
Feb 03, 05
16:31 ET	Abgenix to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
Feb 05, 01
21:00 ET	Abgenix and Celltech Enter Technology Licensing and Co-Development Agreement
Jan 30, 01
20:33 ET	Abgenix Reports Year End 2000 Financial Results
16:30 ET	Abgenix Reports Year End 2000 Financial Results
Jan 29, 01
16:31 ET	Abgenix Enters Exclusive Manufacturing Agreement With Lonza Biologics
Jan 22, 01
16:30 ET	Abgenix Announces 2000 Year-End Financial Results Conference Call
Jan 09, 01
07:00 ET	Abgenix Extends Antibody Collaboration With Amgen
07:00 ET	Abgenix Extends Antibody Collaboration With Pfizer
Jan 05, 01
16:30 ET	Raymond M. Withy Promoted to President of Abgenix
Jan 03, 01
16:30 ET	Abgenix to Proceed With Phase IIb Study of ABX-IL8 in Psoriasis
Jan 02, 01
16:30 ET	Abgenix Receives Additional Patent Grant for XenoMouse(TM) Technology
Dec 28, 00
16:30 ET	Abgenix Initiates Phase IIa Clinical Trial With ABX-IL8 For Patients With Rheumatoid Arthritis
Dec 11, 00
16:08 ET	Abgenix Added to Nasdaq-100 Index and Nasdaq-100 Index Tracking Stock
Nov 14, 00
16:30 ET	Abgenix Acquires IntraImmune for $9 Million
Nov 06, 00
16:30 ET	Abgenix Completes Acquisition of ImmGenics
Nov 01, 00
19:30 ET	Abgenix Announces $230 Million Private Placement
Oct 23, 00
20:00 ET	Abgenix Reports Third Quarter 2000 Results
Oct 02, 00
16:00 ET	Abgenix Reaches Antibody Milestone With Pfizer
Sep 26, 00
16:58 ET	Abgenix to Acquire Immgenics in Stock Swap Transaction
Sep 21, 00
16:44 ET	Abgenix Names Gayle Mills Vice President, Business Development
Sep 20, 00
17:36 ET	Abgenix Names John Meyer Vice President, Human Resources
Sep 06, 00
10:35 ET	ImmunoGen and Abgenix Form Broad Collaboration
Jul 25, 00
07:02 ET	Abgenix Reports Second Quarter 2000 Results
Jul 12, 00
18:30 ET	Abgenix and Lexicon Genetics Form Alliance for Antibody Drug Discovery Using Knowledge of Human Gene Function
Jun 27, 00
07:00 ET	Abgenix Announces Second U.S. Patent
Jun 09, 00
07:00 ET	Abgenix Announces Two-for-One Stock Split
May 22, 00
07:00 ET	Abgenix Enters XenoMouse(TM) Technology Collaboration With Abbott to Generate Fully Human Antibodies
May 19, 00
07:00 ET	Abgenix and SB Enter XenoMouse Technology Collaboration
May 15, 00
07:00 ET	Abgenix Names Gregory Landes, Ph.D. Vice President, Product Discovery
May 10, 00
07:00 ET	Abgenix Names Patrick Murphy Vice President, Manufacturing
May 02, 00
08:00 ET	Abgenix and Genzyme Transgenics Sign Agreement For Transgenic Antibody Production
Apr 25, 00
08:02 ET	Abgenix Reports First Quarter Results
Apr 13, 00
08:00 ET	Abgenix Names Dr. Steven Chamow Vice President of Process Sciences
Apr 03, 00
08:03 ET	Abgenix Initiates Phase II Clinical Trial With ABX-IL8 in Psoriasis
Mar 21, 00
08:02 ET	Abgenix and Corixa Form Alliance to Discover and Develop Therapeutic Monoclonal Antibodies
Mar 06, 00
16:24 ET	Abgenix and Millennium Form Broad Human Antibody Collaboration
Mar 01, 00
18:53 ET	Abgenix Announces Two-for-One Stock Split
08:01 ET	Abgenix Announces the Exercise of Over-Allotment Option for the Purchase Of 450,000 Shares of Common Stock
Feb 28, 00
18:30 ET	Abgenix Extends Antibody Collaboration With Pfizer
Feb 18, 00
19:41 ET	Abgenix Reports Year End Results
Feb 10, 00
20:49 ET	Abgenix Announces the Sale of 3,000,000 Shares of Common Stock in a Follow-On Public Stock Offering
Jan 28, 00
09:22 ET	Abgenix Files Common Stock Offering of Up to 2.5 Million Shares
Jan 18, 00
08:00 ET	Abgenix and Gliatech Enter XenoMouse Technology Collaboration
Jan 10, 00
08:01 ET	Abgenix and Elan Enter XenoMouse Technology Collaboration to Generate Fully Human Antibody Therapy for Neurological Diseases
Dec 22, 99
19:39 ET	Abgenix and Japan Tobacco Receive Early Hart-Scott-Rodino Clearance
Dec 20, 99
16:05 ET	Abgenix to Become Sole Owner of XenoMouse Fully Human Antibody Technology
Dec 09, 99
06:30 ET	Abgenix and CuraGen Establish Large-Scale Drug Development Alliance; Companies to Develop Genomics-based Human Antibody Drugs
Dec 07, 99
18:07 ET	Abgenix Initiates Phase III Clinical Trial of Graft Versus Host Disease Therapy
Dec 01, 99
07:00 ET	Abgenix and Chiron Enter XenoMouse Technology Collaboration
07:00 ET	Human Genome Sciences and Abgenix Enter a Broad Collaboration to Create Fully Human Antibody Therapeutics
Nov 30, 99
17:15 ET	Abgenix Reports Positive Clinical Data With ABX-IL8 in Psoriasis
Nov 15, 99
09:39 ET	Abgenix Announces $75 Million Private Placement
Nov 10, 99
21:06 ET	Abgenix Contemplates Private Placement of Common Stock
Nov 02, 99
11:19 ET	Abgenix and Pfizer Add a Third Antigen Target to Their Collaboration
Oct 26, 99
06:00 ET	Abgenix Reports Third Quarter Results
Oct 21, 99
08:01 ET	Abgenix Names Dr. Gisela Schwab Vice President of Clinical Development
Oct 13, 99
08:00 ET	Abgenix and U.S. Army Expand Infectious Disease Collaboration
Oct 05, 99
08:00 ET	Abgenix Completes ABX-IL8 Phase I/II Clinical Trial in Psoriasis
Sep 13, 99
08:30 ET	Abgenix Reports Encouraging Preclinical Results With ABX-IL8
Aug 18, 99
00:42 ET	Abgenix Receives Patent on Method for Making Mice That Generate Fully-Human Antibodies
Jul 27, 99
00:44 ET	Abgenix Reports Second Quarter Results
Jul 19, 99
00:46 ET	Abgenix Files IND for Phase I Clinical Trial in Cancer With ABX-EGF
Jul 13, 99
00:48 ET	Abgenix and U.S. Army Collaborate on Development of Antibody Countermeasures To Biological Weapons
Jun 30, 99
00:53 ET	Abgenix and Japan Tobacco Collaborate on ABX-IL8 Clinical Development
Jun 15, 99
08:29 ET	Abgenix Completes Enrollment of ABX-IL8 Phase I/II Clinical Trial in Psoriasis
Jun 03, 99
03:02 ET	Abgenix, Inc. Adopts a Stockholder Rights Plan
May 18, 99
03:04 ET	Abgenix Reports Positive Survival Data From a Phase II Trial of ABX-CBL In Graft Versus Host Disease
Apr 27, 99
03:38 ET	Abgenix Reports First Quarter Results
Apr 26, 99
03:24 ET	Abgenix Enters Research Collaboration With Amgen
Apr 07, 99
03:41 ET	Abgenix Announces the Exercise of Over-Allotment Option for Public Offering Of Common Stock
Mar 26, 99
03:16 ET	Abgenix Enters Research Collaboration With BASF
Mar 15, 99
03:21 ET	Abgenix Reports Encouraging Preclinical Results With ABX-EGF In Cancer Research
Mar 04, 99
04:11 ET	Abgenix, Inc. Announces the Sale of 3,000,000 Shares in a Public Stock Offering
Feb 16, 99
03:34 ET	Abgenix Reports ABX-IL8 Safe and Well Tolerated in a Phase I Clinical Trial Of Psoriasis Patients
Feb 04, 99
03:31 ET	Abgenix Reports Positive Preliminary Results From a Phase II Trial of ABX-CBL In Graft Versus Host Disease
Jan 28, 99
03:29 ET	Abgenix Initiates Phase I Clinical Trial With ABX-IL8 in Rheumatoid Arthritis Patients
Jan 27, 99
03:44 ET	Abgenix Files Registration Statement for Public Offering
03:43 ET	Abgenix and Genentech Form Multi-Product Collaboration in Antibody Field
Jan 26, 99
05:42 ET	Abgenix Reports Year End Results
03:35 ET	Abgenix Reports Year End Results
Jan 07, 99
03:14 ET	Abgenix and AVI BioPharma Sign License Agreement to Develop Human Antibody to Treat Cancer
Dec 28, 98
03:19 ET	Abgenix Signs Research Agreement With Centocor
Dec 16, 98
03:39 ET	Abgenix and Research Corporation Technologies to Collaborate on Human Antibody For Immune Tolerance
Dec 15, 98
03:32 ET	Abgenix Completes Phase II Clinical Trial in GVHD
Nov 30, 98
03:20 ET	Abgenix Initiates Phase I/II Clinical Trial in Psoriasis
Nov 20, 98
03:18 ET	Cell Genesys Receives $9.5 Million From Sale of Abgenix Stock
Oct 27, 98
03:36 ET	Abgenix Reports Third Quarter Results
Oct 26, 98
03:23 ET	Abgenix and Pfizer Add a Second Antigen Target to Their Collaboration
Oct 15, 98
03:13 ET	Abgenix and Millennium BioTherapeutics Form Collaboration
Aug 04, 98
01:44 ET	Abgenix Demonstrates Significance of Multiple Antibody Genes With XenoMouse Technology
Jul 30, 98
08:36 ET	Abgenix Announces Inititation of Company Website
04:15 ET	Abgenix Announces the Exercise of Over-Allotment Option for Public Offering Of Common Stock
Jul 15, 98
04:20 ET	Abgenix and Millennium BioTherapeutics Form Collaboration
Jul 02, 98
04:23 ET	Abgenix, Inc. Announces the Sale of 2,500,000 Shares of Common Stock
Apr 21, 98
08:22 ET	Abgenix Forms Research Collaboration With Genentech
Apr 06, 98
08:26 ET	Abgenix, Inc. Files Registration Statement for Initial Public Offering
Feb 02, 98
06:23 ET	Abgenix Signs Agreement Eith Schering-Plough
Jan 06, 98
06:23 ET	Abgenix Begins Confirmatory Phase II Trial of ABX-CBL Antibody
Dec 31, 97
06:24 ET	Abgenix Signs License Agreement With Pfizer
Dec 23, 97
06:25 ET	Abgenix Raises $20 Million in Private Placement
Apr 07, 97
01:36 ET	Dr. John Lipani Joins Abgenix Management Team
Mar 31, 97
01:28 ET	Abgenix Acquires Antibody Product for Transplant Rejection